Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pomalidomide Celgene

- PMLiVE

Johnson & Johnson to expand dermatology portfolio with $850m Proteologix acquisition

The company will gain access to two treatments for atopic dermatitis

- PMLiVE

Johnson & Johnson shares positive results for TAR-200 in high-risk bladder cancer

More than 83,000 cases of bladder cancer are diagnosed in the US every year

- PMLiVE

J&J’s Rybrevant combination recommended by CHMP to treat advanced lung cancer

The fully-human EGFR-MET bispecific antibody has been recommended as a first-line treatment option

- PMLiVE

J&J and Legend’s Carvykti receives EC approval to treat relapsed and refractory multiple myeloma

The BCMA-targeted therapy is the first to receive approval in Europe for RRMM patients as early as first relapse

- PMLiVE

NICE recommends Menarini’s Nexpovio combination to treat multiple myeloma

More than 4,500 new patients are diagnosed with this form of blood cancer every year in the UK

- PMLiVE

BMS and 2seventy’s multiple myeloma therapy Abecma receives expanded FDA approval

More than 35,700 new cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

J&J and Legend’s Carvykti approved by FDA for expanded multiple myeloma use

The cell therapy is the first and only BCMA-targeted therapy to be approved for this condition as early as first relapse

- PMLiVE

Johnson & Johnson to expand cardiovascular capabilities with $13.1bn Shockwave acquisition

Cardiovascular disease results in an estimated 17.9 million global deaths every year

- PMLiVE

Johnson & Johnson’s Opsynvi granted FDA approval in pulmonary arterial hypertension

The rare form of pulmonary hypertension is responsible for up to 1,000 new cases in the US every year

- PMLiVE

Bristol Myers Squibb announces EC approval for multiple myeloma therapy Abecma

Approximately 50,000 cases of the blood cancer are diagnosed in Europe every year

- PMLiVE

J&J and Protagonist’s JNJ-2113 shown to maintain skin clearance in plaque psoriasis

More than 125 million people worldwide are estimated to be living with the immune-mediated skin disorder

- PMLiVE

GSK announces positive results for Blenrep in head-to-head multiple myeloma study

About 176,000 new cases of the blood cancer are diagnosed globally each year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links